First AD

Second AD

Surbhi Sidana, MD, is an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University in California.

Peter Voorhees, MD, is a member of the Hematology Department at Atrium Health Levine Cancer Institute and a professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.Peter Voorhees, MD

Bridging to CAR T in R/R MM: Best Practices

Video content above is prompted by the following:

In preparing patients to receive CAR T, what is your optimal strategy for bridging therapy?

Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place 

OncLive Insights

Experts discuss their optimal strategy for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T-cell therapy. They focus on selecting therapies that maintain disease control while awaiting CAR T infusion.

Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

Explaining CAR T: Key Points for Patient Counseling

Overcoming Barriers to CAR T Referral in R/R MM

Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM